CA15-3在乳腺癌早期诊断、预后评估和术后监测复发转移中的应用价值

被引：10

作者：

王玉娇

夏添松

刘晓安

机构：

[1] 南京医科大学第一附属医院乳腺病科

来源：

江苏医药 | 2016年 / 42卷 / 06期

关键词：

D O I：

10.19460/j.cnki.0253-3685.2016.06.023

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

糖链抗原15-3(CA15-3)是临床最为常用的乳腺癌相关血清肿瘤标志物之一。虽然临床并不推荐其常规用于乳腺癌的早期诊断和筛查,但CA15-3与乳腺癌患者预后相关。本文综述CA15-3在乳腺癌早期诊断、预后评估和术后监测复发转移方面的意义。

引用

收藏

页码：683 / 685

页数：3

相关论文

共 9 条

[1]

Evaluation of tumor markers (HER-2/neu oncoprotein; CEA; and CA 15.3) in patients with locoregional breast cancer: prognostic value..Molina Rafael;Augé Jose M;Escudero Jose M;Filella Xavier;Zanon Gabriel;Pahisa Jaume;Farrus Blanca;Muoz Montserrat;Velasco Martin;.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.2010,

[2]

Epidemiological and Clinicopathological Trends of Breast Cancer in Chinese Patients During 1993 to 2013 A Retrospective Study [J].

Si, Wen ;

Li, Ying ;

Han, Yingjie ;

Zhang, Fan ;

Wang, Yingzhe ;

Li, Ying ;

Linghu, Rui Xia ;

Zhang, Xingyang ;

Yang, Junlan .

MEDICINE, 2015, 94 (26)

[3]

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer [J].

Geng, Biao ;

Liang, Man-Man ;

Ye, Xiao-Bing ;

Zhao, Wen-Ying .

MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (01) :232-236

[4]

Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers [J].

Lee, Jun Sang ;

Park, Seho ;

Park, Ji Min ;

Cho, Jung Hoon ;

Kim, Seung Il ;

Park, Byeong-Woo .

BREAST CANCER RESEARCH AND TREATMENT, 2013, 141 (03) :477-484

[5]

Prognostic role of CA15.3 in 7942 patients with operable breast cancer [J].

Sandri, M. T. ;

Salvatici, M. ;

Botteri, E. ;

Passerini, R. ;

Zorzino, L. ;

Rotmensz, N. ;

Luini, A. ;

Mauro, C. ;

Bagnardi, V. ;

Cassatella, M. C. ;

Bottari, F. ;

Casadio, C. ;

Colleoni, M. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (01) :317-326

[6]

Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer [J].

Molina, Rafael ;

Auge, Jose M. ;

Farrus, Blanca ;

Zanon, Gabriel ;

Pahisa, Jaume ;

Munoz, Montserrat ;

Torne, Aureli ;

Filella, Xavier ;

Escudero, Jose M. ;

Fernandez, Pedro ;

Velasco, Martin .

CLINICAL CHEMISTRY, 2010, 56 (07) :1148-1157

[7]

CA 15-3: Uses and limitation as a biomarker for breast cancer.[J].Michael J. Duffy;Denis Evoy;Enda W. McDermott.Clinica Chimica Acta.2010, 23

[8]

Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer [J].

Uehara, Masahiro ;

Kinoshita, Takayuki ;

Hojo, Takashi ;

Akashi-Tanaka, Sadako ;

Iwamoto, Eriko ;

Fukutomi, Takashi .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (05) :447-451

[9]

Tumour marker guided salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study [J].

Nicolini, A ;

Carpi, A ;

Michelassi, C ;

Spinelli, C ;

Conte, M ;

Miccoli, P ;

Fini, M ;

Giardino, R .

BIOMEDICINE & PHARMACOTHERAPY, 2003, 57 (10) :452-459